Switch theme
Sign up to access all valuation multiples
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
2017
750
LTM Revenue $140M
LTM EBITDA -$302M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Idorsia has a last 12-month revenue of $140M and a last 12-month EBITDA of -$302M.
In the most recent fiscal year, Idorsia achieved revenue of $172M and an EBITDA of -$288M.
Idorsia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Idorsia valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $110M | $172M | XXX | XXX | XXX |
| Gross Profit | n/a | $103M | XXX | XXX | XXX |
| Gross Margin | NaN% | 60% | XXX | XXX | XXX |
| EBITDA | -$886M | -$288M | XXX | XXX | XXX |
| EBITDA Margin | -806% | -167% | XXX | XXX | XXX |
| Net Profit | -$718M | -$936M | XXX | XXX | XXX |
| Net Margin | -654% | -543% | XXX | XXX | XXX |
| Net Debt | $1.1B | $1.1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Idorsia's stock price is CHF 1 (or $1).
Idorsia has current market cap of CHF 236M (or $267M), and EV of CHF 1.4B (or $1.6B).
See Idorsia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $267M | XXX | XXX | XXX | XXX | $-1.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Idorsia has market cap of $267M and EV of $1.6B.
Idorsia's trades at 11.2x LTM EV/Revenue multiple, and -5.2x LTM EBITDA.
Analysts estimate Idorsia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Idorsia and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 9.1x | XXX | XXX | XXX |
| EV/EBITDA | -5.5x | XXX | XXX | XXX |
| P/E | -0.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpIdorsia's NTM/LTM revenue growth is 52%
Idorsia's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Idorsia's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Idorsia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Idorsia and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 57% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -167% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -67% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -115% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 249% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 193% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 452% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Idorsia acquired XXX companies to date.
Last acquisition by Idorsia was XXXXXXXX, XXXXX XXXXX XXXXXX . Idorsia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Idorsia founded? | Idorsia was founded in 2017. |
| Where is Idorsia headquartered? | Idorsia is headquartered in Switzerland. |
| How many employees does Idorsia have? | As of today, Idorsia has 750 employees. |
| Who is the CEO of Idorsia? | Idorsia's CEO is Mr. Jean-Paul Clozel. |
| Is Idorsia publicy listed? | Yes, Idorsia is a public company listed on SWX. |
| What is the stock symbol of Idorsia? | Idorsia trades under IDIA ticker. |
| When did Idorsia go public? | Idorsia went public in 2017. |
| Who are competitors of Idorsia? | Similar companies to Idorsia include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Idorsia? | Idorsia's current market cap is $267M |
| What is the current revenue of Idorsia? | Idorsia's last 12-month revenue is $140M. |
| What is the current EBITDA of Idorsia? | Idorsia's last 12-month EBITDA is -$302M. |
| What is the current EV/Revenue multiple of Idorsia? | Current revenue multiple of Idorsia is 11.2x. |
| What is the current EV/EBITDA multiple of Idorsia? | Current EBITDA multiple of Idorsia is -5.2x. |
| What is the current revenue growth of Idorsia? | Idorsia revenue growth between 2023 and 2024 was 57%. |
| Is Idorsia profitable? | Yes, Idorsia is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
